Physician profile
James D Walter
NPI 1912009580
$1,667.17
in general payments reported to CMS, 2019-2025
28 companies · $73.21 in 2025
The $73.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $178 · 2021: $618 · 2022: $161 · 2023: $94.46 · 2024: $242 · 2025: $73.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $246.33 | 2019-2025 | Ubrelvy, Vraylar |
| Astellas Pharma US INC | $157.47 | 2019-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $150.71 | 2019-2021 | |
| Horizon Therapeutics Plc | $147.35 | 2019-2022 | |
| Amgen INC. | $138.10 | 2019-2024 | Repatha |
| Glaxosmithkline, LLC. | $111.73 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $89.89 | 2021 | |
| Novo Nordisk INC | $68.08 | 2020-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $65.60 | 2019-2021 | |
| Lilly USA, LLC | $56.17 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $53.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $45.15 | 2019-2022 | |
| Mylan Specialty L.P. | $39.07 | 2021-2022 | |
| Dexcom, INC. | $33.75 | 2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $32.52 | 2024 | Nuzyra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.46 | 2019-2020 | |
| Indivior INC. | $21.88 | 2024 | Sublocade |
| Amarin Pharma, INC. | $21.53 | 2021 | |
| Abbott Laboratories | $20.49 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $19.24 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.91 | 2020 | |
| Radius Health, INC. | $15.40 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.33 | 2021 | |
| Pacira Therapeutics, INC. | $13.74 | 2019 | |
| Allergan, INC. | $13.52 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.24 | 2024 | Zoryve |
| Sunovion Pharmaceuticals INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.